- Home
- LILA vs AUPH Comparison
LILA vs AUPH Comparison
Compare LILA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILA | AUPH |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | Bermuda | Canada |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | LILA | AUPH |
|---|---|---|
| Price | $7.99 | $16.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $9.75 | ★ $17.25 |
| AVG Volume (30 Days) | 343.2K | ★ 1.4M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | ★ $4,433,000,000.00 | $265,808,000.00 |
| Revenue This Year | $1.62 | $21.22 |
| Revenue Next Year | N/A | $15.40 |
| P/E Ratio | ★ N/A | $29.41 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $4.26 | $6.55 |
| 52 Week High | $9.04 | $16.48 |
Technical Indicators
Market Signals| Indicator | LILA | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.31 | 62.79 |
| Support Level | $8.29 | $15.57 |
| Resistance Level | $8.75 | $16.07 |
| Average True Range (ATR) | 0.25 | 0.49 |
| MACD | -0.09 | -0.07 |
| Stochastic Oscillator | 1.83 | 85.29 |
Price Performance
Historical ComparisonAbout LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.